Aiming to activate the immune system to target chronic inflammation. Taking a fresh approach to treating cancer and autoimmune disease.
Qu Biologics is working to develop a new platform of immunotherapeutic treatments. Our novel Site Specific Immunomodulators (SSIs) are being designed with the goal of activating the body’s immune system to reverse the chronic inflammation underlying many conditions including cancer and autoimmune diseases.
Qu Biologics’ SSIs have been administered to patients with advanced cancer and moderate to severe autoimmune disease, through a compassionate use program. The preliminary findings from these uncontrolled, unblinded data suggest that the program was associated with some promising outcomes which support further study in controlled clinical trials. Qu Biologics is recruiting participants for their first clinical trial in Crohn’s disease. For more information, please visit www.qucrohnstrial.com.
If safety and efficacy are demonstrated, Qu Biologics’ SSIs have the potential to improve the survival and quality of life of millions of patients fighting cancer and the quality of life of patients living with debilitating autoimmune diseases such as Crohn’s disease, ulcerative colitis and rheumatoid arthritis.